Scarica l'app Stockscreener
10.80
2.81%
0.295
Dopo l'orario di chiusura:
10.98
0.18
+1.67%
Precedente Chiudi:
$10.51
Aprire:
$10.49
Volume 24 ore:
210.35K
Relative Volume:
2.07
Capitalizzazione di mercato:
$57.03M
Reddito:
-
Utile/perdita netta:
$-74.56M
Rapporto P/E:
-5.8965
EPS:
-1.8316
Flusso di cassa netto:
$-60.27M
1 W Prestazione:
+58.82%
1M Prestazione:
+132.20%
6M Prestazione:
+121.82%
1 anno Prestazione:
+93.97%
Intervallo 1D:
$10.35
$10.95
Intervallo di 1 settimana:
$6.66
$11.49
Portata 52W:
$1.7608
$11.49
Rallybio Corp Stock (RLYB) Company Profile
Nome
Rallybio Corp
Settore
Industria
Telefono
203- 859-3820
Indirizzo
234 CHURCH STREET, NEW HAVEN
Compare RLYB vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
10.80 | 55.47M | 0 | -74.56M | -60.27M | -1.8316 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-09 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-05-15 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-02-07 | Downgrade | Jefferies | Buy → Hold |
| 2023-04-17 | Iniziato | H.C. Wainwright | Buy |
| 2023-04-10 | Iniziato | Wedbush | Outperform |
| 2022-12-09 | Iniziato | JP Morgan | Overweight |
| 2022-02-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-08-23 | Iniziato | Cowen | Outperform |
| 2021-08-23 | Iniziato | Evercore ISI | Outperform |
| 2021-08-23 | Iniziato | Jefferies | Buy |
Mostra tutto
Rallybio Corp Borsa (RLYB) Ultime notizie
$105M for Starface pimple patches, humanoid robot maker eyes €1B and Rallybio's reverse merger - Axios
Candid Therapeutics to Merge with Rallybio in Reverse Merger - themiddlemarket.com
Rallybio Investor Alert: Merger Investigation Launched - National Today
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio CorporationRLYB - The AI Journal
Candid lists via Rallybio reverse merger, adds $505m financing - The Pharma Letter
Candid Therapeutics: $505 Million Financing And Merger With Rallybio To Advance Autoimmune T-Cell Engager Pipeline - Pulse 2.0
TPG group shows 7.2% Rallybio (RLYB) stake and supports Candid merger - Stock Titan
RLYB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rallybio merger deal includes $50M breakup fee, $200M financing floor - Hartford Business Journal
Rallybio to acquire Candid Therapeutics - Yahoo Finance
Latham & Watkins Advises on US$505 Million Financing in Connection With Rallybio-Candid Therapeutics Merger - Legal Desire Media and Insights
Rallybio, Candid Therapeutics announce merger agreement - TipRanks
Firm Advises Candid Therapeutics on Patent Matters Related to Acquisition by Rallybio - Wilson Sonsini
Rallybio and Candid Therapeutics To Merge - citybiz
Candid, in a reverse merger with RallyBio, to go public - BioPharma Dive
Rallybio to acquire Candid Therapeutics in $505M deal - Investing.com
Candid Therapeutics Strikes Up Merger With Rallybio to Advance Its Autoimmune Drug Pipeline - MedCity News
Rallybio: Merger forms a TCE therapeutics leader with $500M+ capital to advance autoimmune disease pipeline - TradingView
Rallybio: Merger forms a top TCE therapeutics company with $700M cash, advancing a broad autoimmune pipeline - TradingView
Candid scores Nasdaq listing via reverse merger Rallybio - Fierce Biotech
Rallybio to merge with San Diego biotech in deal backed by $505M in financing - Hartford Business Journal
Rallybio to Merge with Candid Therapeutics in All-Stock Deal - TipRanks
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders - The AI Journal
Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism - Benzinga
Rallybio Corporation (NASDAQ:RLYB) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
Merger: Rallybio (RLYB) to combine with Candid with $505.5M concurrent financing - Stock Titan
Rallybio to Merge With Candid Therapeutics; Candid Holders to Own ~57.6% of Combined Company - TradingView
Candid Therapeutics, Rallybio (NASDAQ: RLYB) in $505M cash-backed merger - Stock Titan
Candid to go public via reverse merger with Rallybio - Endpoints News
Nvidia and Coherent announce a strategic partnership to jointly develop advanced optical technologies, aiming to drive the scaled development of next-generation data center architectures. - Bitget
Rallybio Corporation and Candid Therapeutics announce merger agreement - marketscreener.com
Rallybio Corporation And Candid Therapeutics Announce Merger Agreement - TradingView
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement - Business Wire
RLYB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
5AM Ventures revises Rallybio (RLYB) ownership and discloses stock sales - Stock Titan
Rallybio’s RLYB116 Clears Phase 1 Milestone, Sharpening Its Autoimmune Pipeline - TipRanks
RLYB PE Ratio & Valuation, Is RLYB Overvalued - Intellectia AI
Rallybio's Strategic Pivot: Clinical Milestones and Financial Runway in Focus - AD HOC NEWS
Rallybio (RLYB) Price Target Increased by 700.00% to 8.16 - Nasdaq
Lieber, Rallybio CFO, sells $3992 in shares By Investing.com - Investing.com Canada
Lieber, Rallybio CFO, sells $3992 in shares - Investing.com
Rallybio (RLYB) CFO gets 2,500-share award, sells 789 shares for taxes - Stock Titan
Rallybio (NASDAQ: RLYB) director granted options in lieu of cash - Stock Titan
What is Rallybio Corporation’s valuation compared to sector2025 Market Trends & Daily Volume Surge Signals - mfd.ru
Affibody’s licensee Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement - Cision News
Rallybio reports positive phase 1 results for subcutaneous C5 inhibitor By Investing.com - Investing.com Canada
Rallybio reports positive phase 1 results for subcutaneous C5 inhibitor - Investing.com Australia
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement - BioSpace
Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026 - Benzinga
Rallybio announces positive data for RLYB116 phase 1 study - marketscreener.com
Weekly Rallybio shot fully shuts down terminal complement in early trial - Stock Titan
Rallybio Corp Azioni (RLYB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):